Evidence Explorer / MS-N200 / Supportive physical care / Appraised November 1, 2026
A six-site proof-of-concept trial tested an app-controlled, wearable transcutaneous electrical nerve stimulation (TENS) device for chronic painful CIPN. The prespecified primary symptom score did not show a conventional statistically significant between-group benefit.
Evidence at a glance
- Population: adults with chronic CIPN; 142 randomized and treated, 130 completed six weeks.
- Intervention: wearable device below the knee, targeted to about five hours of wear daily; active stimulation was 60–100 Hz.
- Comparator: sham device with only brief stimulation.
- Primary result: EORTC-CIPN20 between-group difference 1.05 points (95% CI −0.56 to 2.67; P=.199).
- Evidence label: inconclusive proof-of-concept evidence.
What was studied
The trial was subject- and assessor-blinded and registered as NCT04367480. Participants used the device for six weeks. Ninety-one percent completed follow-up.
The primary EORTC-CIPN20 comparison did not meet the usual P<.05 threshold. The investigators had selected a liberal alpha of .20 for this screening study, which is appropriate for deciding whether to study an intervention further but not for declaring established clinical benefit.
Exploratory pain and cramp comparisons favored active treatment by roughly 1.2–1.4 points, but confidence intervals crossed zero and P values were .110–.128. Tingling and numbness did not clearly improve.
What this evidence cannot establish
This was a short proof-of-concept study, not a definitive effectiveness trial. The primary result, exploratory analyses and clinical importance of the numerical differences need to be kept separate.
It does not show prevention of neuropathy during chemotherapy, nerve recovery, reduced falls, less opioid use or improved cancer outcomes.
Practical safety context
The trial excluded people with acute symptomatic deep-vein thrombosis, more than 2+ leg edema, leg wounds or ulcers, a pacemaker, epilepsy or pregnancy. Those exclusions are a practical reminder that a commercial device should not be used casually.
Ask the treating team about implanted electrical devices, seizure history, skin integrity, blood clots, marked edema and whether the painful area is safe for electrode placement.
Questions for the care team
- Is the goal pain relief, function, sleep, or another outcome we can measure?
- Are there device or skin contraindications in my case?
- How long should a supervised trial last before deciding it is not helping?
Sources
- PubMed: wearable TENS trial — PMID 37993030
- Full text in PubMed Central — PMCID PMC11058028
- Journal article — DOI 10.1016/j.jpain.2023.11.014
- ClinicalTrials.gov record — NCT04367480
Source note: Full text, registry information and PubMed metadata were checked. Funding and conflict information is reported only where it was available in the checked source. No correction, retraction or expression of concern was identified in the PubMed-linked record on November 1, 2026.
This record is educational. It is not a personal treatment recommendation and does not replace advice from the oncology or radiation-care team. Symptom or toxicity outcomes do not demonstrate tumor response, recurrence prevention or longer survival.
